Related Experiment Video
Updated: Feb 26, 2026

07:42
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
3.8K
Mild Cognitive Impairment and Driving Cessation: A 3-Year Longitudinal Study
Michael H Connors1, David Ames, Michael Woodward
1Dementia Collaborative Research Centre, School of Psychiatry, UNSW Australia, Sydney, NSW, Australia.
Dementia and Geriatric Cognitive Disorders
|July 25, 2017
Summary
Driving cessation is common in older adults with mild cognitive impairment (MCI). Age, cognitive decline, and functional impairment predict driving cessation, not solely dementia progression.
Area of Science:
- Gerontology
- Neurology
- Cognitive Science
Background:
- Driving cessation in older adults is linked to significant health issues.
- Individuals with mild cognitive impairment (MCI) face heightened risks associated with driving cessation.
- Limited research exists on driving behaviors and cessation in the MCI population.
Purpose of the Study:
- To identify key predictors of driving cessation among individuals diagnosed with mild cognitive impairment.
- To understand the factors influencing driving cessation in a cohort of people with MCI.
Main Methods:
- 185 individuals with MCI were recruited from Australian memory clinics.
- Driving status, cognition, function, neuropsychiatric symptoms, and medication use were tracked over 3 years.
- Data collection involved participants and their carers.
Main Results:
- Out of 144 participants still driving at baseline, 50 (27.0%) ceased driving within 3 years.
- Predictors of driving cessation included older age, increased cognitive and functional impairment, and a steeper decline in these measures at 6 months.
- 58% of those who stopped driving were later diagnosed with dementia, with cessation often occurring post-diagnosis.
Conclusions:
- A substantial percentage of individuals with MCI stop driving within 3 years, independent of dementia development.
- Accessible factors like age, cognitive status, and functional ability, along with their 6-month changes, are significant predictors of driving cessation.
Related Concept Videos
Cognitive Development During Adulthood
973
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
973
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
720
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
720

